Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of vaginal atrophy in women with cardiovascular pathology risk

一种阴道萎缩、心血管的技术，应用在心血管系统疾病、有机活性成分、非有效成分的医用配制品等方向，能够解决不推荐等问题，达到降低风险、治疗泌尿生殖系统萎缩的效果

Inactive Publication Date: 2012-01-18
FARMAC ITALY
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently marketed vaginal estriol preparations are usually administered at a dose of 0.5 mg / day (500 μg / day) for 2 to 3 weeks at the beginning of treatment, followed by 0.5 mg each time, 2 or 3 times a week. drug, but because of its risks, it is not recommended for women with cardiovascular disease or a high risk of developing cardiovascular disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of vaginal atrophy in women with cardiovascular pathology risk
  • Treatment of vaginal atrophy in women with cardiovascular pathology risk
  • Treatment of vaginal atrophy in women with cardiovascular pathology risk

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] Within the scope of the present invention, a history of cardiovascular disease and / or at least one established risk factor, namely: increased age (women older than 50 or 60 years), genetic predisposition (e.g. family history of cardiovascular disease, cardiovascular disease related gene mutations), complications (such as severe migraine with aura, hypertension, hypercholesterolemia, hypertriglyceridemia, insulin-dependent diabetes mellitus, heart disease, heart valve disease, etc.) and lifestyle ( Such as smoking, sedentary, obesity, high-fat diet, etc.) women are considered to be women with a high probability of developing cardiovascular disease (CVD).

[0020] More specifically, within the scope of the present invention, cardiovascular disease includes any disease or disorder of the cardiovascular system that is associated with the effects of estrogen or that may be considered a contraindication to estrogen therapy. Examples include coronary artery disease (or CHD), c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the capacity to self-limit the absorption of estriol, for the prevention and / or the treatment of urogenital atrophy in women said women having a high probability of suffering from a cardiovascular pathology or suffering or having suffered from a cardiovascular pathology.

Description

[0001] The present invention relates to the use of estriol in the preparation of a pharmaceutical preparation capable of self-limiting the absorption of estriol for vaginal administration. The preparation is useful for the prevention and / or treatment of urogenital atrophy in women who are at high risk of developing cardiovascular disease or who have or have suffered from cardiovascular disease. Background technique [0002] Estrogen and other female hormones are mainly produced in the ovaries and act in different tissues and organs throughout life. Cells in these organs have receptors for estrogen and other hormones, with the breasts and uterus having the most. Estrogens exert their effects by binding to said receptors and initiating different physiological or pathological processes. Among other physiological functions, they lead to the development and changes of the breast and uterus in different life stages (puberty, pregnancy, lactation, menopause). But estrogens can also...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/566A61K9/52A61P15/02
CPCA61K31/566A61K47/32A61K9/0034A61P15/00A61P15/02A61P15/08A61P9/00A61K31/565
Inventor 阿尔瓦里奥·阿塞夫龙费尔南德斯多洛雷斯·布兰科洛萨姆海梅·莫斯科索德尔普拉多康塞普西翁·涅托马格罗
Owner FARMAC ITALY